logo
The doctor fighting for women's health on Ukraine's front line

The doctor fighting for women's health on Ukraine's front line

Yahoo5 hours ago
In a rural village close to the Ukrainian front line, a group of women queue quietly outside a purple and white ambulance, waiting to be seen by a doctor with his shaved head dyed the blue and yellow of the Ukrainian flag.
For many of them, it's their first time seeing a doctor since the war began more than three years ago.
Since 2022, Dr Serhii Baksheiev, 53, has carried out more than 1,000 gynaecological examinations on women throughout front-line and occupied areas in his kitted out mobile clinic - named 'The Feminine Shuttle' and complete with a bright pink examination chair.
"This is a humanitarian volunteering mission. It's for people who need help, in places where there are no doctors or hospitals, and it's absolutely free," he says.
The war with Russia has placed a huge strain on Ukraine's healthcare system, with more than 1,940 attacks on health facilities since the invasion, according to the World Health Organization (WHO) - making it the highest number in any humanitarian crisis to date - and with a significant increase in those attacks since December 2023.
When the war began, Dr Baksheiev, who is an obstetrician and gynaecologist, initially spent his days in a bunker in Kyiv helping to deliver babies as bombs fell above.
'They took shrapnel from my heart' – the magnets saving lives in Ukraine
'It's Groundhog Day': Ukraine's sky defenders stuck in relentless battle
The idea for an on-the-road clinic came to him, he says, after later medical volunteer missions to the front line revealed the lack of facilities because medical centres and hospitals had been completely destroyed.
"We went to Kharkiv and Chernihiv, which were very damaged, and the most difficult thing was not being able to provide gynaecological services because there were no tools and equipment, because everything was ruined," he says.
Dr Baksheiev and his team would have to use anything available as an examination table, including old sofas, meaning he would have to kneel on the floor to conduct examinations.
Today, walking around the electric vehicle, it's clear Dr Baksheiev is incredibly proud of its capabilities: it's been kitted out with everything he and his team could need in these remote areas, including an ultrasound machine and medical equipment to carry out minor surgeries.
During a two-day mission the team can perform up to 80 colposcopies - where they examine the cervix and vulva for signs of cancerous or pre-cancerous tissue.
The work is crucial to the people living in these remote areas.
His visits to small rural villages occupied by the Russians are often carried out in secret. He and his team slip in for a day or two to carry out their examinations and leave before they are detected.
Figures provided by Ukraine's public health ministry and seen by the BBC show detection rates for ovarian and cervical cancers are down by 17% and 10% respectively since 2020.
And when doctors like Dr Baksheiev do get into those areas to perform examinations, they are finding a higher than average incidence of malignant tumours.
On average, up to 4% of all women are diagnosed with malignant tumours after being examined, according to FRIDA Ukraine, the medical organisation Dr Baksheiev volunteers for.
Dr Ulana Supron was Ukraine's health minister from 2016 to 2019. She says there is a concern about the "ticking time bomb" of health outcomes as the war drags on.
"In the public health community, there definitely is a lot of worry about what's going to happen as the war continues," she says.
"Not only in terms of physical health, but also mental health - because there is a constant stress, constant psychological trauma happening."
Dr Supron says the government has managed to partially or fully rebuild as many as 964 medical facilities that were damaged by Russia.
"They're working closely with the WHO and with other international organisations to try to come up with a plan on how we can rebuild the health system that was in place prior to Russia's invasion," she adds.
Despite a cancer diagnosis himself in September 2024, Dr Baksheiev continues to volunteer and provide treatment to women across the country.
"Apart from the medical examination, you also hear them out because a lot of patients have stories about how the Russians attacked their villages," he says.
"So we are not only doctors, we're the therapists for these patients."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Groundbreaking' drug could slow down progression of type 1 diabetes
‘Groundbreaking' drug could slow down progression of type 1 diabetes

Yahoo

timean hour ago

  • Yahoo

‘Groundbreaking' drug could slow down progression of type 1 diabetes

A 'groundbreaking' drug to slow down the development of type 1 diabetes is being tried by a handful of patients in the UK. Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment​ for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'

Samsung to buy US healthcare services company Xealth
Samsung to buy US healthcare services company Xealth

Yahoo

timean hour ago

  • Yahoo

Samsung to buy US healthcare services company Xealth

SEOUL (Reuters) -Samsung Electronics said on Tuesday it had signed an agreement to acquire Xealth, a U.S.-based healthcare platform, as part of its efforts to expand its mobile healthcare services business. The South Korean company did not disclose the value of the transaction. Samsung said the two companies hoped to create "synergy between Samsung's advanced wearable technology and Xealth's digital health platform" which runs digital health programs and manages data linking care providers, including more than 500 U.S. hospitals, with their patients. The acquisition comes as Samsung steps up efforts to diversify beyond its core semiconductor and smartphone businesses. Samsung has been betting on the medical sector as one of its new growth engines, along with consumer audio, cooling and heating systems, and robotics. In May, Samsung Electronics agreed to buy Germany's FlaktGroup for 1.5 billion euros ($1.68 billion) as it looks to meet growing demand for cooling of data centres used for artificial intelligence projects. Samsung, led by Chairman Jay Y. Lee, said at a shareholder meeting in March that it was looking for "meaningful" deals this year to drive growth after having lagged rivals in tapping the AI chip boom led by Nvidia. Samsung earlier on Tuesday projected a far worse-than- expected 56% plunge in second-quarter operating profit due to weak AI chip sales, deepening investor concerns over the tech giant's ability to revive its struggling semiconductor business.

Exclusive-WeightWatchers names new medical chief, plans to offer menopause therapy and support
Exclusive-WeightWatchers names new medical chief, plans to offer menopause therapy and support

Yahoo

time2 hours ago

  • Yahoo

Exclusive-WeightWatchers names new medical chief, plans to offer menopause therapy and support

By Amina Niasse NEW YORK (Reuters) -WeightWatchers will announce on Tuesday Dr. Kim Boyd as its chief medical officer, and plans for a new program to help women manage the transition into menopause and beyond, part of its growth strategy in emerging from bankruptcy. Boyd, a Stanford University graduate who has worked with several consumer health startups, said in an interview that WeightWatchers is building upon its decades-long work providing weight management tools to also address the specific needs of people using obesity treatments. That includes Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The company says its model promoting balanced eating and exercise helps subscribers reduce gastrointestinal side effects from the medicines and lose more weight on Wegovy. 'We have the foundation, and we will continue to evolve our programming to show up in a way that matches best with the addition of medications,' Boyd said. WeightWatchers CEO Tara Comonte said such support for members using weight-loss drugs should appeal to health insurers and employers who pay for health benefits as they seek more sustainable management of the costly medications. "It's a different business model and these partnerships and relationships take a much longer period of time than dialing up some direct to consumer marketing or promotional models," Comonte said. The program for perimenopause, menopause and post-menopause will include access to prescription treatments such as hormone replacement therapy, as well as behavioral and nutritional support for members, a significant proportion of whom are women ages 40 to 60 years old, WeightWatchers said. More details will become available later this year, the company, also known as WW International, said. 'It is a very natural overlap. In the perimenopausal and menopausal phase, up to 70% of women experience weight gain,' Boyd said. CHANGING WEIGHT LOSS MARKET Boyd previously served as national medical director at One Medical, a clinical business now owned by and later was chief medical officer at weight-management company Calibrate. Her appointment comes nearly a year after previous Chief Medical Officer Dr. Amy Meister stepped down. In the interim, WeightWatchers emerged from Chapter 11 bankruptcy, after struggling to compete with other online weight-management platforms selling cheaper, compounded versions of obesity treatments, including telehealth companies like Hims & Hers Health. The market for weight-management companies is changing since the U.S. Food and Drug Administration ordered an end to sales of compounded versions of Wegovy in late May. WeightWatchers last month announced a partnership with Novo Nordisk to sell Wegovy through the drugmaker's NovoCare pharmacy. Hims & Hers continues to offer smaller doses of compounded Wegovy than what is available from Novo, arguing they are providing a personalized medication that is not subject to the FDA ban. Industry analysts, however, have questioned whether that strategy will leave Hims vulnerable to legal challenges. Hims has said it also plans to expand into testosterone and menopause treatments as part of its growth strategy in the coming years. WeightWatchers has stopped selling compounded weight-loss drugs, and its partnership with Novo may prove more attractive to employer-sponsored health plans in the long run, Boyd said. "At the foundation of this is prescribing FDA-approved medications," Comonte said. 'We only prescribe branded drugs." A month's supply of Wegovy is listed at over $1,000 per month, but many people pay less through insurance. Cash-pay patients can access the treatment for $499 through NovoCare. 'For employers, some of them are finding value in these vendors like WeightWatchers... that give the members the lifestyle tools,' said Chantell Reagan, a senior director at advisory firm Willis Towers Watson. These strategies may help an employee sustain weight loss if they stop using a drug, she said. 'We are looking very closely at our employers that are using these programs and assessing the effectiveness.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store